Health Catalyst, Inc (HCAT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 26/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.39% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 3 Unprofitable Stocks That Fall Short
- Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks
- 3 Small-Cap Stocks We Steer Clear Of
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
- 3 Value Stocks That Concern Us
- Health Catalyst appoints new CEO
- Health Catalyst to Participate in Upcoming Investor Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Facilitated Transitions to Postpartum Primary Care and Mental Health Care Services: Secondary Analysis of a Randomized Clinical Trial. — JAMA Netw Open 2026 Aug 3 PMID 42640640
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Health Catalyst, Inc.
Full HCAT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.